Working... Menu

LBH Phase II in Small Cell Lung Cancer (SCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01222936
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : October 18, 2010
Novartis Pharmaceuticals
Information provided by:
Southern Europe New Drug Organization

Brief Summary:

SCLC is the most aggressive and lethal form of lung cancer, typically very sensitive to cytotoxic therapy when first diagnosed, but associated with a high incidence of tumour relapse and a very poor life expectancy. Combination chemotherapy based on cisplatin or carboplatin and etoposide represents the most widely used regimen. Despite of the high response rate, approximately 80% of patients with limited disease and nearly all patients with extended disease develop disease relapse or progression. Topotecan is, at present, the only approved second line treatment in Europe.

The search of a new therapeutic agent that could alter the natural history of SCLC would be an important goal to be reached. LBH589 (Panobinostat) is a histone deacetylase (HDAC) inhibitor available for intravenous and oral administration. LBH589 could be classified as PAN-DAC inhibitor targeting both histone and non histone proteins and as such it could be suitable for combination with cytotoxics. Three phase I dose escalation studies with both the intravenous and the oral formulation of LBH589, examining various dose schedules of administration have been conducted in advanced solid tumours and haematological malignancies.

Single agent activity was observed in phase I in patients with haematological cancer. In solid tumours one response (Hormone-refractory Prostatic Cancer) and some prolonged stabilizations have been observed with intravenous formulation. Phase II studies are now in progress.

Condition or disease Intervention/treatment Phase
Small Cell Lung Carcinoma Drug: LBH581 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Patients With Advanced Small Cell Lung Cancer (SCLC)
Study Start Date : May 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Intervention Details:
  • Drug: LBH581
    25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
    Other Name: Panobinostat

Primary Outcome Measures :
  1. Objective response rate [ Time Frame: 12-18 weeks (foreseen participation of the patient in the study) ]
    Objective response rate measured according to the RECIST (Response Evaluation Criteria In Solid Tumours).

Secondary Outcome Measures :
  1. Duration of antitumor activity [ Time Frame: 12-18 weeks (foreseen participation of the patient in the study) ]
    Time-to-progression, duration of response and disease stabilization

  2. Drug safety profile [ Time Frame: 28 days following the last dose ]
    Evaluation of adverse events, physical examination, vital signs, concomitant medications, laboratory (hematology and chemistry) and instrumental data (i.e. ECG) considered for safety analyses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological/cytological diagnosis of SCLC, mixed small and non small cell tumours are excluded
  2. ≤ 2 prior chemotherapy lines
  3. Progression after, and not during, last previous chemotherapy treatment
  4. Age ≥ 18 and ≤ 75 years
  5. Life expectancy of at least 3 months
  6. ECOG Performance Status 0-1
  7. At least one measurable lesion according to modified RECIST criteria defined as ≥ 1 lesion with longest diameter ≥ 20 mm by conventional techniques or ≥ 10 mm with spiral CT scan. In case of solitary measurable lesion, histological confirmation is not required.
  8. Adequate haematological function:

    • haemoglobin ≥ 9 g/dl
    • platelet count ≥ 100,000/mm3
    • neutrophils count ≥ 1,500/mm3
  9. Adequate liver and renal functions:

    • Total serum bilirubin ≤ 1.5 x UNL
    • Serum creatinine ≤ 1.5 x UNL or 24 hours creatinine clearance ≥ 50 mL/min
    • AST and ALT ≤ 2.5 x UNL or ≤ 5.0 x UNL if the transaminase elevation is due to hepatic involvement
    • Albumin ≥ 2.5 g/dl
    • Alkaline phosphatase ≤ 2.5 x UNL
  10. Fertile patients must use effective contraception during and for ≥ 6 weeks after completion of study therapy
  11. Ability to signed informed consent

Exclusion Criteria:

  1. Progression while on previous chemotherapy
  2. Other chemotherapy treatment < 4 weeks prior to enrolment
  3. Presence of active infection
  4. A known history of HIV positivity
  5. Participation to any investigational drug study < 4 weeks preceding study enrolment
  6. Radiotherapy involving > 30% of the active bone marrow
  7. Thoracic and brain radiotherapy < 4 weeks prior to enrolment. Palliative radiotherapy is allowed during study treatment
  8. Presence of any serious neurological or psychiatric disorder
  9. Impaired cardiac function, including any one of the following:

    • Complete Left Bundle Branch Block or obligate use of a cardiac pacemaker or congenital long QT syndrome or history or presence of atrial or ventricular tachyarrhythmias or clinically significant resting bradycardia (< 50 beats per minute) or QTcF > 480 msec on screening ECG or Right Bundle Branch block + left anterior hemiblock (biphasic block)
    • Acute MI ≤ 3 months prior to starting study drug
    • Other clinically significant heart disease (e.g. congestive heart failure, previous history angina pectoris, uncontrolled hypertension, history of labile hypertension or arrhythmia, or history of poor compliance with an antihypertensive regimen)
    • Any other case of current abnormal cardiac functionality or history of cardiac disease causing LVEF < 45% as determined by ECHO
  10. Known hypersensitivity/allergic reaction to the study product
  11. Presence of uncontrolled intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study.
  12. Previous or current concomitant malignancy at other site, other than basal or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix, within 3 years.
  13. Symptomatic or progressive brain metastases
  14. Patients with an active bleeding diathesis or on anticoagulants Therapeutic doses of sodium warfarin (Coumadin) are not allowed. Low doses of Coumadin (e.g., ≤ 2 mg/day) for line patency are allowed
  15. Pregnant or lactating women
  16. Concomitant use of CYP3A4/5 inhibitors or inducers, or drug that prolong the QT interval and/or induce torsades ventricular arrythmia, where the treatment can not be discontinued or switched to a different medication prior to starting study drug.
  17. Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GMCSF) ≤ 2 weeks prior to starting study drug.
  18. Unable or unwilling to comply with all study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01222936

Layout table for location information
Klinik für Onkologie und Haematologie
Frankfurt am Main, Germany, 60488
Klinikum Kassel Innere Medizin
Kassel, Germany, 34125
Azienda Ospedaliera "S. G. Moscati"
Avellino, AV, Italy, 83100
Istituto Nazionale Ricerca sul Cancro
Genova, GE, Italy, 16132
U.O. di Oncologia Medica
Palermo, PA, Italy, 90141
Ospedale Maggiore di Parma
Parma, PR, Italy, 43100
Azienda Ospedaliera San Camillo Forlanini
Rome, RM, Italy, 00151
Az. San. Ospedaliera Molinette S. Giovanni Battista di Torino
Torino, TO, Italy, 10126
Sponsors and Collaborators
Southern Europe New Drug Organization
Novartis Pharmaceuticals
Layout table for investigator information
Study Chair: Filippo De Marinis, MD Azienda Ospedaliera San Camillo Forlanini

Layout table for additonal information
Responsible Party: Scientific Director, SENDO Tech s.r.l. Identifier: NCT01222936     History of Changes
Other Study ID Numbers: S075LBH501
First Posted: October 18, 2010    Key Record Dates
Last Update Posted: October 18, 2010
Last Verified: October 2010

Keywords provided by Southern Europe New Drug Organization:
Small Cell Lung Carcinoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Small Cell Lung Carcinoma
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Histone Deacetylase Inhibitors
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action